UroToday - Overactive Bladder (OAB)

Home

Overactive Bladder (OAB)

Overactive Bladder

UroToday's Overactive Bladder section is a repository of the clinical publications, clinical trials and investigative science pertaining to the diagnosis and treatment of overactive bladder. Also available are conference coverage for all timely overactive bladder science, audio podcasts and downloadable slides from UroToday's slide library.

Online Urology & Urologic Oncology Journal
Please read about the UroToday International Journal; We welcome submissions year round and are committed to providing fast-tracked, peer reviewed publication.
Kind regards,
Christian Gratzke, MD
Associate Section Editor Overactive Bladder
UroToday International Journal

Display

results per page

Results 151 - 165 of 671

<< Start < Prev 11 12 13 14 15 16 17 18 19 20 Next > End >>

AUA 2009 - Urodynamics/Incontinence/Female Urology: Urodynamic Testing - Detection of Hypoxia and Ischemia within the Detrusor Using Near Infrared Spectroscopy (NIRS) - Session Highlights
Friday, 01 May 2009
CHICAGO, IL, USA (UroToday.com) - Dr. Andrew Macnab presented the work of the University of British Columbia group on near-infrared spectroscopy (NIRS).
read more

AUA 2009 - Urodynamics/Incontinence/Female Urology: Urodynamic Testing - Ultrasound Imaging and Female Urodynamics – Technique, Feasibility and Patient Acceptance - Session Highlights
Friday, 01 May 2009
CHICAGO, IL, USA (UroToday.com) - Dr. Lewis Chan from Australia presented his experience with the use of translabial ultrasound imaging of the bladder and urethra during urodynamic studies.
read more

AUA 2009 - Urodynamics/Incontinence/Female Urology: Urodynamic Testing - Identification of Measures of Bladder Sensation in Patients with Overactive Bladder - Session Highlights
Friday, 01 May 2009
CHICAGO, IL, USA (UroToday.com) - In light of the current focus and work on defining the role of afferent signals in overactive bladder (OAB), it is important to consider methods by which the sensory aspect of OAB may be defined and quantified.
read more

AUA 2009 - Urodynamics/Incontinence/Female Urology: Non-Neurogenic Voiding Dysfunction - Patient-Selected Goals and Goal Achievement: A New Perspective on Outcome in Overactive Bladder Patients - Session Highlights
Friday, 01 May 2009
CHICAGO, IL, USA (UroToday.com) - Dr. Soo Hyun Lim and her colleagues from Seoul, Korea explored the important concept of patient reported goal achievement (PGA) as it pertained to overactive bladder (OA) treatment.
Login to read more...

AUA 2009 - Urodynamics/Incontinence/Female Urology: Non-Neurogenic Voiding Dysfunction - Intravesical Liposomal (LP08) Instillation Protects Bladder Urothelium From Chemical Irritation - Session Highlights
Friday, 01 May 2009
CHICAGO, IL, USA (UroToday.com) - Dr. Jonathan Kaufman from Pittsburgh, together with his colleagues from Royal Oak, MI, presented work based on previous studies that have demonstrated therapeutic effects of liposomes (LP08) instilled into bladders with protamine-induced overactivity (PS).
Login to read more...

AUA 2009 - Urodynamics/Incontinence/Female Urology: Neurogenic Voiding Dysfunction - Combination Drug Therapy Improves Compliance in the Neurogenic Bladder - Session Highlights
Friday, 01 May 2009
CHICAGO, IL, USA (UroToday.com) - Dr. Anne Cameron and colleagues from the University of Michigan suggested an improved positive effect of combination therapy using antimuscarinic agents with imipramine (relaxation of the bladder via unknown mechanisms) and/or α blockade over monotherapy with antimuscarinics alone in the neurogenic bladder.
read more

AUA 2009 - Urodynamics/Incontinence/Female Urology: Neurogenic Voiding Dysfunction - Nerve Growth Factor Levels is Correlated with Severity of Neurological Impairment in Patients with Cerebrovascular Accident - Session Highlights
Friday, 01 May 2009
CHICAGO, IL, USA (UroToday.com) - Two other groups evaluated urinary biomarkers in the neurogenic patient population based on their study that found elevated urinary nerve growth factor (NGF) in patients who had suffered cerebrovascular accidents (CVA).
read more

AUA 2009 - Urodynamics/Incontinence/Female Urology: Neurogenic Voiding Dysfunction - Transplantation of Olfactory Mucosa Following Spinal Cord Injury Improves Voiding Efficiency in Rat - Session Highlights
Friday, 01 May 2009
CHICAGO, IL, USA (UroToday.com) - The best-of-session winner, the abstract presented by Dr. Jiro Nakayama and colleagues from Suita, Japan introduced the fascinating concept of olfactory mucosal transplantation for treatment of neurogenic bladder due to spinal cord injury.
read more

AUA 2009 - Urodynamics/Incontinence/Female Urology: Neurogenic Voiding Dysfunction - The Role of Sensory Pathways in the Development of Cross-Sensitization Between the Urinary and Gastrointestinal Systems - Session Highlights
Friday, 01 May 2009
CHICAGO, IL, USA (UroToday.com) - The pelvic floor medicine scientific session at the AUA covered a variety of interesting topics ranging from the emerging role of afferent pathways in overactive bladder (OAB) to follow-up on a variety of techniques for both male and female pelvic floor reconstruction to biomarkers in neurogenic an idiopathic bladder overactivity.
read more

AUA 2009 - Urodynamics/Incontinence/Female Urology: Brain Responses to Bladder Filling Measured by Functional Magnetic Resonance Imaging Reflect Clinical Severity of Urge Incontinence - Session Highlights
Wednesday, 29 April 2009
CHICAGO, IL, USA (UroToday.com) - Urinary incontinence and its treatment continue to play a vital role in a urology practice.
Login to read more...

Verathon® Introduces BladderScan® BVI 9600 Bladder Volume Instrument with AortaScan™ Mode to Help Physicians Identify the Presence of Abdominal Aortic Aneurysms
Wednesday, 29 April 2009
BOTHELL, WA, USA (Press Release) - March 23, 2009
read more

Verathon® Introduces BladderScan® BVM 9500 Bladder Volume Instrument To Help Urologists Diagnose Bladder Dysfunction
Wednesday, 29 April 2009
BOTHELL, WA, USA (Press Release) - April 28, 2009
read more

New Data Presented at AUA's Annual Conference Prove GELNIQUE™ (oxybutynin chloride) 10% gel is an Effective, Safe Option for Female Overactive Bladder (OAB) Patients
Monday, 27 April 2009
CHICAGO, IL, USA (Press Release) - April 27, 2009
read more

New National Survey Shows That Overactive Bladder Symptoms Are Pervasive and Difficult to Manage
Friday, 24 April 2009
CHICAGO, IL, USA (Press Release) - April 24, 2009
read more

Urodynamic Findings in Female Diabetic Patients With and Without Overactive Bladder Symptoms - Abstract
Friday, 24 April 2009
Department of Urology, National Taiwan University Hospital, Taipei, Taiwan.
read more

Focus on Overactive Bladder

Focus on Overactive Bladder condenses a selection of compelling and relevant science - on topic and chosen by the UroToday.com editorial staff.

Podcast - Effective Darifenacin Treatment after Dissatisfaction with Prior Extended-Release Antimuscarinic Therapy

World Continence Week 2009

Patient Guide - Controlling Your Bladder Symptoms

- Prepared by Diane K. Newman, MSN, CRNP, FAAN, BCIA-PMDM

Promoting Continence Worldwide

- Prepared by Diane K. Newman, MSN, CRNP, FAAN, BCIA-PMDM

Urinary Incontinence: Epidemiology and Disease Burden
- Prepared by Alan J. Wein, MD, PhD (hon)

Differential Pharmacological Effects of Antimuscarinic Drugs on Heart Rate: A Randomized, Placebo-Controlled, Double-Blind, Crossover Study with Tolterodine and Darifenacin in Healthy Participants > or = 50 years
- by Brian Olshansky, MD

Darifenacin Treatment for Overactive Bladder in Patients Who Expressed Dissatisfaction With Prior Extended-Release Antimuscarinic Therapy
- by Norman Zinner, MD, et al.

Suburothelial Myofibroblasts in the Human Overactive Bladder and the Effect of Botulinum Neurotoxin Type A Treatment
- by Alexander Roosen, MD and Clare J. Fowler, MD

A Systematic Review and Meta-Analysis of Randomized Controlled Trials with Antimuscarinic Drugs for Overactive Bladder
- by Giacomo Novara, MD, FEBU

Emerging Drugs for Treatment of Overactive Bladder and Detrusor Overactivity
- by Marcus Drake, MD

Two Types of Urgency
- by Philip M. Hanno, MD, MPH - Editor's Pick

Long-Term Efficacy and Safety of Tolterodine in Children with Neurogenic Detrusor Overactivity
- by Pasquale Casale, MD

Defining Overactive Bladder as Hypersensitivity
- by Philip M. Hanno, MD, MPH

Minimally Invasive Therapy for Neurogenic Detrusor Overactivity: A Review
- by Karl-Erik Andersson, Roger Dmochowski and Alan Wein

A Randomized Controlled Study of Posterior Tibial Nerve Stimulation for Overactive Bladder
- by Paula Palma, MD, PhD. et al.

Efficacy and Tolerability of Add-On Trospium Chloride in Patients with Benign Prostate Syndrome and Overactive Bladder: A Noninterventional Trial Showing Use of Flexible Dosing
- by Ulrich Schwantes, PhD, et al.

The second-line management of idiopathic overactive bladder: What is the place of sacral neuromodulation and botulinum toxin-A in contemporary practice?

On the Origins of the Sensory Output from the Bladder: The Concept of Afferent Noise

A Review of Adherence to Drug Therapy in Patients with Overactive Bladder

Sacral Neuromodulation for Treating the Symptoms of Overactive Bladder Syndrome and Non-Obstructive Urinary Retention: More Than 10 Years of Clinical Experience

Urine cytokines suggest an inflammatory response in the overactive bladder: a pilot study
- by Michael Chancellor, MD, et al.

Obesity is associated with a more severe overactive bladder disease state that is effectively treated with once-daily administration of trospium chloride extended release
- by Michael G. Oefelein, MD, et al.

Ten years single surgeon experience with botulinum toxin in the urinary tract; clinical observations and research discovery
- by Michael Chancellor, MD.

The evolution of transdermal therapy for overactive bladder
- by Peter K. Sand, MD

Outcome of a Randomized, Double-Blind, Placebo Controlled Trial of Botulinum A Toxin for Refractory Overactive Bladder
- by Michael K. Flynn, MD, et al.

InterStim Therapy: A Contemporary Approach to Overactive Bladder
- by Neeraj Kohli, MD, MBA and Danielle Patterson, MD

Differential Pharmacological Effects of Antimuscarinic Drugs on Heart Rate: A Randomized, Placebo-Controlled, Double-Blind, Crossover Study with Tolterodine and Darifenacin in Healthy Participants > or = 50 years
- by Brian Olshansky, MD, et al.

Randomized Comparison of Tolterodine With Vaginal Estrogen Cream Versus Tolterodine Alone for the Treatment of Postmenopausal Women With Overactive Bladder Syndrome
- by Ling-Hong Tseng, MD, et al.

The role of industry funding in randomized controlled trials of antimuscarinic medications for overactive bladder
- Session Highlight by Ariana L. Smith, MD from the International Continence Society (ICS) 39th Annual Meeting

State of the Art Lecture: Bladder re-innervation: Can new nerves improve the function of the neurogenic bladder?
- Session Highlight by Ariana L. Smith, MD from the International Continence Society (ICS) 39th Annual Meeting

Is ultrasound bladder wall thickness a better measure than urodynamics for overactive bladder symptoms?
- Session Highlight by Ariana L. Smith, MD from the International Continence Society (ICS) 39th Annual Meeting

Urodynamics/Incontinence/Female Urology: Urodynamic Testing - Identification of Measures of Bladder Sensation in Patients with Overactive Bladder
- Session Highlight by Kathleen Kobashi, MD from the 2009 Annual Meeting of the American Urological Association (AUA)

Session Highlights from the Society for Urodynamics & Female Urology 2009 Winter Meeting
- Exclusive Coverage by UroToday Contributing Medical Editor, William Jaffe, MD

The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) at The National Institutes of Health (NIH) - UI Symposium
- Session Highlights Reported by Diane K. Newman

Drug Treatment - Lecture Series

- Presented by Karl-Erik Andersson, MD, PhD, and Christopher Chapple, MD, et al. at the Fourth International Consultation on Incontinence (ICI)

Drug Treatment - Committee Meeting Highlights

- Reported by William Jaffe, MD from the Fourth International Consultation on Incontinence (ICI)

Voiding Dysfunction Session Highlights

- From the American Urological Association 2008 Annual Meeting

Urodynamics and Reality

- Presented by Ed McGuire, MD, at the 32nd Winter Urologic Forum

Clinical Proof of Concept Study (BLOSSOM) Shows Novel Beta 3 Adrenoceptor Agonist YM178 is Effective and Well Tolerated in the Treatment of Symptoms of Overactive Bladder
- Presented at the European Association of Urology - 23rd Annual EAU Congress

International Consultation on Incontinence - ICI 2008
- Session Abstracts, Overactive Bladder